Saxenda (liraglutide) is a GLP-1 agonist injection pen medication used to support long-term weight loss in adults with obesity, adults with overweight and weight-related health issues, and certain ...

A new, injectable weight-loss drug has been approved by the U.S. Food and Drug Administration. The agency on Tuesday approved Saxenda (liraglutide) for adults who are obese or for those who are ...

Ozempic has become so embedded in global culture that “Ozempic face” was shortlisted for a prominent dictionary’s word of the ...

European regulators have recommended an update to the label of Novo Nordisk’s weight loss drug, Saxenda, to include information about the active ingredient’s ability to reduce cardiovascular risk.

COPENHAGEN (Reuters) -Novo Nordisk's new obesity drug Wegovy, far more efficient at causing weight loss in patients than similar drugs on the market, could capture sales of its existing obesity ...

Novo Nordisk’s liraglutide is one drug with two names. With last week’s approval of Saxenda, Novo is planning to unveil the second of the two brands in the liraglutide franchise, this one labeled for ...

Please provide your email address to receive an email when new articles are posted on . Reduced body weight and improved metabolic control were found with once-daily subcutaneous Saxenda as an add-on ...

THE HSE has splashed out over €200million on weight-loss jabs in less than three years. And it’s emerged that 80,000 patients ...

Sydney mother-of-one Hannah Mitchel was having trouble shifting the weight she had gained as a result of the antidepressants she was on. Despite making a number of lifestyle changes, including doing ...